Zealand Pharma A/S Overview
Pro stress-test →Zealand Pharma is a biotechnology company engaged in discovery, development, and commercialization of peptide-based medicines focusing on gastrointestinal and metabolic diseases. The company maintains a portfolio with commercial products and multiple candidates in late-stage development aimed at addressing unmet medical needs.
Strategic Profile
Pro stress-test →Unlike many small biotechs, Zealand utilizes a partnership model to mitigate risk and maximize distribution. The company entered a transformative collaboration with Roche to co-develop and co-commercialize petrelintide, aiming to redefine the standard of care for people with overweight and obesity by establishing the leading amylin-based franchise around petrelintide.
Competitive Landscape
Pro stress-test →Zealand has gained substantial attention due to its promising pipeline positioning it as a key competitor in the GLP-1 and weight-loss space. Compared to peers, Zealand is viewed as more agile and R&D-focused than diversified giants, lacking the massive current revenue of Eli Lilly but offering specialized focus on next-generation peptides.
Industry Context
Zealand Pharma A/S operates in Biotechnology - Specialty Pharma (Obesity & Metabolic Health).
Key facts
Founded: 1997 · Headquarters: Søborg, Denmark · Employees: 481 · Revenue: $1.44B · Market cap: $3.46B